Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 2/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095247 | 0.85 | HTR2C (0.90) | HTR2CHRH4PIK3CAPRKCITSHR | |
| SCHEMBL614900 | 0.79 | HTR2C (1.00) | HTR2CHRH4PIK3CAPRKCITOP1 | |
| SCHEMBL2923518 | 0.72 | HTT (0.70) | HTR2CTSHRKMT2AKDM4EALDH1A1 | |
| SCHEMBL19038471 | 0.72 | ALDH1A1 (0.49) | HRH4PIM1PIM2KMT2AKDM4E | |
| SCHEMBL14307605 | 0.71 | HRH4 (0.80) | HRH4PIM1PIM2 | |
| SCHEMBL2392391 | 0.70 | PIK3CA (0.73) | HTR2CHRH4PIK3CAPRKCITSHR | |
| SCHEMBL2920098 | 0.70 | CYP1A2 (0.52) | HTR2CHRH4TSHRKMT2ANPSR1 | |
| SCHEMBL2918593 | 0.70 | CYP1A2 (0.67) | HTR2CKMT2AKDM4EALDH1A1 | |
| SCHEMBL4343440 | 0.70 | HRH4 (0.72) | HTR2CHRH4 | |
| SCHEMBL4086517 | 0.68 | MAP2K7 (0.57) | HTR2CHRH4NPSR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | disclosed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | ARGENTA DISCOVERY LTD. (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269239-A1 | Pyrimidine Compounds as Histamine Modulators | HRH4, HRH3, HRH2 | HTR2C 138/4885HRH4 1/4885PIM1 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.